Evidence map›Paper›PMID 42206679›Full record

Trial reportMovement disorders : official journal of the Movement Disorder Society2026

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz and 10 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Simon RoweFaculty of Medicine and Health, University of New South Wales, Sydney, Australia.
Amy EvansDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Saeed KayhanianDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Philip C ButteryDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Robert MorrisDepartment of Neurosurgery, Cambridge University Hospitals, Cambridge, United Kingdom.
Katie AndresenDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Laura SherlockDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Samuel HewittDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Tagore NakornchaiDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Marwan HarizUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Kyriacos MitrophanousOxford Biomedica (UK) Limited, Oxford, United Kingdom.
Ludvic ZrinzoUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Matthew ApplebyUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Phil WoodgateUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Seema MaruUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Patricia LimousinUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Christine GirgesUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Thomas FoltynieUCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.ORCID https://orcid.org/0000-0003-0752-1813
Stephane PalfiDepartment of Neurosurgery, Henri Mondor Academic Hospital, Université Paris Est Créteil, GRCT OPTIMA, INSERM Laboratory U955 of Translational NeuroPsychiatry, Institut Mondor de Recherche Biomédicale, Créteil, France.
Roger A BarkerDepartment of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.

Funding

National Institute for Health and Care Research NIHR203312Sponsor: Axovant Sciences Ltd; collaborator: Oxford BioMedica (UK) Ltdsponsor: Oxford BioMedica (UK) Ltd; collaborator: Axovant Sciences LtdSponsor: Sio Gene Therapies
6 · The paper itself

Abstract

backgroundSUNRISE-PD was a dose-escalating, phase 1/2 study investigating a second-generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB-102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.

objectivesThe aim was to provide an investigator-led description of the clinical course for the 6 patients enrolled in the OXB-102 trial.

methodsIndividual patient data were extracted, compiled, and summarized from investigator records.

resultsSix patients received a low (n = 2) and a higher (n = 4) dose of the OXB-102 gene therapy. There were eight serious adverse events (SAE), of which only one was considered definitely related to the intervention. All SAEs were transient and resolved without sequelae. Efficacy data were limited, but some stabilization of motor function was observed in most of the patients.

conclusionThis novel dopamine gene therapy appears safe in patients with moderate-to-severe PD, with some possible stabilizing effects on their clinical course. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

DopamineGenetic TherapyParkinson DiseaseAgedFemaleGene Therapy AgentsGenetic VectorsHumansLentivirusMaleMiddle AgedTreatment OutcomeDopamineclinical trialgene therapyParkinson's disease

Identifiers

PMID42206679
PMCPMC13602281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.